New Rare Gene Variants Linked to ALS and MND Risk

Large-scale exome analyses have identified new rare genetic variants that contribute to the risk of amyotrophic lateral sclerosis (ALS). The research, published in Nature, utilized data from 22 cohorts to examine the genetic architecture of the fatal neurodegenerative disease.

The study involved the harmonization and analysis of exome sequencing data from 17,919 individuals with ALS and 200,703 controls across discovery and replication phases.

Researchers found that rare variants with low-to-moderate penetrance are thought to dominate the genetic risk associated with the disorder.

Identification of New Risk Genes

The rare variant analyses identified several new risk genes associated with ALS. Replication phases of the study confirmed the association of the YKT6 gene.

The findings also provided support for the involvement of the following genes:

• HTR3C
• GBGT1
• KNTC1

the research provided strong and independent validation for genes that previously had limited evidence, specifically ARPP21, DNAJC7, and CFAP410.

Specific Variant Effects in ARPP21

Detailed analysis of the ARPP21 gene revealed specific variants that impact the disease. The researchers identified a new high-effect variant designated as p.P747L.

The study also confirmed that the p.P563L variant in ARPP21 is an ALS-associated variant that leads to an aggressive disease course.

Genetic Architecture and Risk Models

The analysis identified risk variants in over 20% of the cases studied. These results support a cumulative oligogenic risk model for the development of ALS.

The study indicates that rare variant analyses capture substantially more genetic risk than common variant genome-wide association studies (GWAS).

These findings highlight new translational targets for future medical research and therapy development for patients with ALS.